RT Journal Article
SR Electronic
T1 Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 38S
OP 45S
DO 10.2967/jnumed.123.266314
VO 65
IS Supplement 1
A1 Zhang, Jingming
A1 Kang, Fei
A1 Wang, Xiao
A1 Chen, Xuejiao
A1 Yang, Xing
A1 Yang, Zhi
A1 Wang, Jing
YR 2024
UL http://jnm.snmjournals.org/content/65/Supplement_1/38S.abstract
AB Radiopharmaceuticals play a critical role in nuclear medicine, providing novel tools for specifically delivering radioisotopes for the diagnosis and treatment of cancers. As the starting point for developing radiopharmaceuticals, cancer-specific biomarkers are important and receive worldwide attention. This field in China is currently experiencing a rapid expansion, with multiple radiotracers targeting novel targets being developed and translated into clinical studies. This review provides a brief overview of the exploration of novel imaging targets, preclinical evaluation of their targeting ligands, and translational research in China from 2020 to 2023, for detecting cancer, guiding targeted therapy, and visualizing the immune microenvironment. We believe that China will play an even more important role in the development of nuclear medicine in the world in the future.